ES2058423T3 - Composicion de factor de crecimiento de fibroblastos, resistente a los acidos, para tratar enfermedades ulcerantes del tracto gastrointestinal. - Google Patents

Composicion de factor de crecimiento de fibroblastos, resistente a los acidos, para tratar enfermedades ulcerantes del tracto gastrointestinal.

Info

Publication number
ES2058423T3
ES2058423T3 ES89115252T ES89115252T ES2058423T3 ES 2058423 T3 ES2058423 T3 ES 2058423T3 ES 89115252 T ES89115252 T ES 89115252T ES 89115252 T ES89115252 T ES 89115252T ES 2058423 T3 ES2058423 T3 ES 2058423T3
Authority
ES
Spain
Prior art keywords
growth factor
fibroblast growth
treating
gastrointestinal tract
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89115252T
Other languages
English (en)
Inventor
Moses Judah Folkman
Koichi Kato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Childrens Medical Center Corp
Original Assignee
Takeda Chemical Industries Ltd
Childrens Medical Center Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd, Childrens Medical Center Corp filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ES2058423T3 publication Critical patent/ES2058423T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

ESTE INVENTO DESCRIBE COMPOSICIONES FARMACEUTICAS Y METODOS DE TRATAR ENFERMEDADES ULCEROSAS DEL APARATO GASTROINTESTINAL EN MAMIFEROS CON UNAS COMPOSICIONES DE FACTOR DE CRECIMIENTO DE FIBROBLASTO RESISTENTE DE ACIDO. TAMBIEN ES DESCRITO EL USO DE COMPOSICIONES DE FACTOR DE CRECIMIENTO DE FIBROBLASTO RESISTENTE DE ACIDO EN EL TRATAMIENTO DE VARIAS OTRAS CONDICIONES SENSIBLES DE FACTOR DE CRECIMIENTO DE FIBROBLASTO.
ES89115252T 1988-08-19 1989-08-18 Composicion de factor de crecimiento de fibroblastos, resistente a los acidos, para tratar enfermedades ulcerantes del tracto gastrointestinal. Expired - Lifetime ES2058423T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23496688A 1988-08-19 1988-08-19
US07/382,263 US5175147A (en) 1988-08-19 1989-07-20 Acid-resistant fgf composition and method of treating ulcerating diseases of the gastrointestinal tract

Publications (1)

Publication Number Publication Date
ES2058423T3 true ES2058423T3 (es) 1994-11-01

Family

ID=26928432

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89115252T Expired - Lifetime ES2058423T3 (es) 1988-08-19 1989-08-18 Composicion de factor de crecimiento de fibroblastos, resistente a los acidos, para tratar enfermedades ulcerantes del tracto gastrointestinal.

Country Status (16)

Country Link
US (2) US5175147A (es)
EP (1) EP0360006B1 (es)
JP (1) JP2501480B2 (es)
KR (1) KR920700040A (es)
CN (1) CN1040741A (es)
AT (1) ATE91628T1 (es)
CA (1) CA1330757C (es)
DE (1) DE68907679T2 (es)
DK (1) DK93890D0 (es)
ES (1) ES2058423T3 (es)
FI (2) FI901949A0 (es)
HU (1) HU207227B (es)
IE (1) IE63046B1 (es)
IL (1) IL91322A (es)
NO (1) NO901710L (es)
WO (1) WO1990001941A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202311A (en) * 1988-08-19 1993-04-13 Children's Medical Center Corporation Stabilized fgf composition
JPH0343088A (ja) * 1989-09-29 1991-02-25 Takeda Chem Ind Ltd ａＦＧＦ蛋白質の製造法
EP0406738A3 (en) * 1989-07-03 1991-08-14 Takeda Chemical Industries, Ltd. Production of acidic fgf protein
CA2020720A1 (en) * 1989-07-13 1991-01-14 Shigeko Yamazaki Method for the purification of therapeutically active recombinant acidic fibroblast growth factor
AUPN271295A0 (en) 1995-05-02 1995-05-25 Gropep Pty Ltd Method of treatment
US5972884A (en) * 1991-03-11 1999-10-26 Creative Biomolecules, Inc. Morphogen treatment of gastrointestinal ulcers
US6399569B1 (en) 1991-03-11 2002-06-04 Curis, Inc. Morphogen treatments for limiting proliferation of epithelial cells
JPH06506939A (ja) * 1991-04-12 1994-08-04 クリエイティブ　バイオモレキュルズ　インコーポレイテッド 血小板由来の成長因子に依る消化管潰瘍の治療方法
NO921495L (no) * 1991-04-16 1992-10-19 Seikagaku Kogyo Co Ltd Oligosakkarid og fremgangsmaate for dets fremstilling
US6190864B1 (en) * 1991-05-08 2001-02-20 Chiron Corporation HCV genomic sequences for diagnostics and therapeutics
US5348941A (en) * 1992-04-01 1994-09-20 Merck & Co., Inc. Stabilizers for fibroblast growth factors
AU685058B2 (en) * 1992-06-16 1998-01-15 Selective Genetics, Inc. Recombinant production of saporin-containing proteins
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
FR2718023B1 (fr) * 1994-03-30 1996-08-14 Paris Val Marne Universite Médicament et composition pharmaceutique pour le traitement de lésions du tractus digestif.
US5783568A (en) * 1994-06-10 1998-07-21 Sugen, Inc. Methods for treating cancer and other cell proliferative diseases
US5531880A (en) * 1994-09-13 1996-07-02 Microelectronics And Computer Technology Corporation Method for producing thin, uniform powder phosphor for display screens
FR2724665B1 (fr) * 1994-09-16 1996-12-20 Rhone Poulenc Rorer Sa Procede de production de proteines recombinantes, plasmides et cellules modifiees
US5593696A (en) * 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
AU2001284914B2 (en) * 2000-08-15 2006-02-09 New Technologies Holdings Pte Ltd Phage-dependent superproduction of biologically active protein and peptides
US7754686B2 (en) * 2000-08-31 2010-07-13 Novartis Vaccines And Diagnostics, Inc. Stabilized FGF formulations containing reducing agents
EP3752174A4 (en) * 2018-02-13 2021-11-17 University of Florida Research Foundation, Incorporated ANALOGUES OF FIBROBLASTS GROWTH FACTOR AND THEIR USES

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296100A (en) * 1980-06-30 1981-10-20 Franco Wayne P Method of treating the heart for myocardial infarction
EP0105014B1 (en) * 1982-09-24 1992-05-20 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Repair of tissue in animals
JPS6034997A (ja) * 1983-05-09 1985-02-22 ジヨージ、ジヨセフ、トダロ 生物学的活性ポリペプチド類
JPS6028999A (ja) * 1983-06-30 1985-02-14 Maruho Kk 細胞増殖促進作用を有するたんぱく質、その組成物と製造方法
US4745098A (en) * 1984-02-24 1988-05-17 The Regents Of The University Of California Compositions and method for improving wound healing
CA1207239A (en) * 1984-08-10 1986-07-08 Upendra K. Banik Gastrointestinal compositions
JPS6172947A (ja) * 1984-09-18 1986-04-15 Takasago Thermal Eng Co Ltd クリ−ンル−ムの形成法およびこの方法に使用する空気調和設備ユニツト
IE66689B1 (en) * 1985-09-12 1996-01-24 Scios Nova Inc Recombinant fibroblast growth factors
DK122687A (da) * 1986-03-14 1987-09-15 Takeda Chemical Industries Ltd Polypeptid, dna og anvendelse deraf
CA1294546C (en) * 1986-04-23 1992-01-21 John S. Sundsmo Wound healing composition containing collagen
NZ220917A (en) * 1986-07-11 1991-05-28 Merck & Co Inc Human and bovine acidic fibroblast growth factor vectors, hosts and compositions
CA1323317C (en) * 1987-01-16 1993-10-19 Allen R. Banks Production of fibroblast growth factor
EP0377579A1 (en) * 1987-07-07 1990-07-18 California Biotechnology, Inc. Recombinant fibroblast growth factors
WO1989004832A1 (en) * 1987-11-24 1989-06-01 Amgen Inc. Analogs of fibroblast growth factor
AU614137B2 (en) * 1988-06-06 1991-08-22 Takeda Chemical Industries Ltd. Stabilized fgf composition and production thereof
JPH0240399A (ja) * 1988-07-27 1990-02-09 Takeda Chem Ind Ltd 線維芽細胞増殖因子ムテインの複合体あるいは組成物

Also Published As

Publication number Publication date
HU207227B (en) 1993-03-29
DE68907679D1 (de) 1993-08-26
EP0360006A2 (en) 1990-03-28
IE892664L (en) 1990-02-19
ATE91628T1 (de) 1993-08-15
IL91322A (en) 1994-12-29
DE68907679T2 (de) 1994-01-27
AU630111B2 (en) 1992-10-22
FI901949A0 (fi) 1990-04-18
HUT55638A (en) 1991-06-28
EP0360006B1 (en) 1993-07-21
FI943028A0 (fi) 1994-06-22
CN1040741A (zh) 1990-03-28
JPH03505736A (ja) 1991-12-12
CA1330757C (en) 1994-07-19
WO1990001941A1 (en) 1990-03-08
US5401721A (en) 1995-03-28
IE63046B1 (en) 1995-03-22
AU4218989A (en) 1990-03-23
EP0360006A3 (en) 1990-04-04
HU895785D0 (en) 1990-12-28
NO901710D0 (no) 1990-04-18
IL91322A0 (en) 1990-03-19
DK93890A (da) 1990-04-17
NO901710L (no) 1990-04-18
JP2501480B2 (ja) 1996-05-29
DK93890D0 (da) 1990-04-17
FI943028A (fi) 1994-06-22
KR920700040A (ko) 1992-02-19
US5175147A (en) 1992-12-29

Similar Documents

Publication Publication Date Title
ES2058423T3 (es) Composicion de factor de crecimiento de fibroblastos, resistente a los acidos, para tratar enfermedades ulcerantes del tracto gastrointestinal.
EP0335901A4 (en) Methods and compositions for the treatment of non-ige-mediated diseases
DE69021386D1 (de) Verfahren und zusammensetzungen zur heilung von geschwüren.
ATE69376T1 (de) Haarwuchsmittel.
NZ223045A (en) Fluticasone propionate compositions with an enteric coating
NL960024I1 (nl) Farmaceutisch preparaat omvattend 3'-deoxythymidine-2'-een (3'-deoxy-2',3'-didehydrothymidine) voor de behandeling van met retrovirus gesmette patiënten.
ATE78696T1 (de) Arzneimittelzubereitung zur behandlung des immunmangels.
PH24568A (en) Use of bezafibrate for treating diabetes
ES520218A0 (es) Un procedimiento para la preparacion de nuevos 2,3-diaril-5-halotiofenos.
ES2063521T3 (es) Mezcla de sustancias con accion terapeutica constituida por compuestos de glutation y antociano.
NO882765L (no) Fremgangsmaate for noeytraliseringsbehandling av svovelsyreinneholdende jernioner.
ES2123004T3 (es) Uso de factor de crecimiento derivado de plaquetas en la preparacion de un medicamento para el tratamiento de ulceras gastrointestinales.
ATE90558T1 (de) Antivirale zusammensetzungen mit aromatischen polycyclischen dionen sowie methode zur behandlung retroviraler infektionen.
TR199802200A2 (xx) S�lfonamid s�bstit�e edilmi� benzopiran t�revleri, �retilme y�ntemi.
AU2126288A (en) Thiosulphinic acid derivatives, their use in the treatment of inflammatory diseases, and drugs containing them
NO164100C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5-klor-s-triazolo-(4,3-a)-pyridin-7-carboxyl-syrer.
NO884635D0 (no) Fremgangsmaate for behandling av most.
EP0200214A3 (en) Treatment of parasitic diseases
ZA815094B (en) Novel peptide
DE59008759D1 (de) Verwendung von interleukin-2 zur behandlung der endotoxinämie.
Burnyasheva et al. On the question of the treatment of urticaria
ES528323A0 (es) Procedimiento para la preparacion de derivados de 6 -metilprednisolona
ATE8399T1 (de) 1,2,4-triazolo(4,3-a)chinolin-1-(2h)-one und diese verbindungen zur pharmazeutischen verwendung.
NO912528D0 (no) Behandling av sykdommer forbundet med jodmangel.
IT8522758A0 (it) Composizione a base di fosfolipidi per la cura di affezioni neurologiche e procedimento per laloro preparazione.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 360006

Country of ref document: ES